Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Yervoy Cuts To The Head Of The Line: Ipilimumab Has Unrestricted Label

Executive Summary

Bristol-Myers Squibb's immunotherapy Yervoy (ipilimumab) will enter the market positioned for wide use, with a broad label for its approval for metastatic melanoma and positive Phase III results for front-line patients.

You may also be interested in...



Champagne Flows As CTLA-4/PD-1 Pioneers Allison And Honjo Win Nobel Prize

Joint prize for MD Anderson's James Allison and Kyoto University's Tasuku Honjo for checkpoint immunotherapy reflects decades of research and billions of IO dollars for industry.

Champagne Flows As CTLA-4/PD-1 Pioneers Allison And Honjo Win Nobel Prize

Joint prize for MD Anderson's James Allison and Kyoto University's Tasuku Honjo for checkpoint immunotherapy reflects decades of research and billions of IO dollars for industry.

Nektar Edges Into Immunotherapy With Better Interleukin-2 Drug

Building on foundation of IL-2 inhibition in immunotherapy, Nektar introduces an improved stimulatory cytokine available on outpatient basis, NKTR-214, for a number of tumor types.

Related Content

Topics

UsernamePublicRestriction

Register

PS053257

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel